



February 24, 2022  
JCR Pharmaceuticals Co., Ltd.

Translation

### Notice of Organizational and Personnel Changes

JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today that organizational and personnel changes effective from April 1, 2022 as follows.

#### 1. Organizational Changes (Attached organizational chart)

In order to conduct more efficient organizational operations in markets where the Sales Division is stable and strong, “Kinki Sales Department” and “West Japan Sales Department” will be merged to form “West Japan Sales Department.” In addition, the Central Japan Sales Department will be renamed to “Tokai Keiji Hokuriku Sales Department” by transferring “Keiji Area”, which has been under the jurisdiction of the Kinki Sales Department. Furthermore, “Cell Regeneration Medical Sales Department” will be abolished, and the marketing information service activities of regenerative medicine products will be transferred to the jurisdiction of the business departments in charge of each region to develop more community-based business activities.

#### 2. Change of Corporate Officer

Name	New Title	Current Title
Yutaka Honda	Corporate Officer Executive Director, Administration Division (reporting to the president) Director, General Affairs Dept.	Corporate Officer Executive Director, Administration Division (reporting to the president)

#### 3. Personnel Changes

Name	New Title	Current Title
Yuichi Kimura	Director, GH Promotion Dept., Sales Division	Director, Tokyo Metropolitan Area Sales Dept. and Manager, Tokyo Kanagawa Area
Hiroyuki Ozaki	Director, Tokai Keiji Hokuriku Sales Dept., Sales Division	Director, Central Japan Sales Dept., Sales Division
Tsuyoshi Tajiri	Director, Tokyo Metropolitan Area Sales Dept., Sales Division	Director, Kinki Sales Dept. and Manager, Hyogo Keiji Area, Sales Division
Syuichi Yasumoto	Director, West Japan Sales Dept., Sales Division	Director, West Japan Sales Dept. and Manager, Kyusyu Okinawa Area, Sales Division

Takeshi Uesaka	Director, East Japan Sales Dept., Sales Division	Director, Cell Regeneration Medical Sales Dept., Sales Division
----------------	--	---

**About JCR Pharmaceuticals Co., Ltd.**

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 46-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, MPS II (Hunter syndrome), acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), Hunter syndrome, Pompe disease, and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

**Cautionary Statement Regarding Forward-Looking Statements**

*This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors’ pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.*

*This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.*

*Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.*

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

[ir-info@jcrpharm.co.jp](mailto:ir-info@jcrpharm.co.jp)

###

# JCR Pharmaceuticals Co., Ltd. Organizational Chart

